Personal statement
EPSRC Early Career Fellow
Iain D.H. Oswald graduated from the University of Edinburgh (2001) and remained there in the group of Professor Simon Parsons to study hydrogen-bonding patterns and co-crystallisation as part of his PhD. Fortunately, this research expanded to investigate the effects of high pressure which allowed him the opportunity to work at the European Synchrotron Radiation Facility in Grenoble. In 2004 he left for Grenoble where he became a postdoctoral researcher on the high pressure beamline (ID27). In 2006, he returned to Edinburgh to join the group of Colin R. Pulham and started a fellowship position funded by the Leverhulme Trust.
In 2009, Iain started his post at SIPBS as a Lecturer in Pharmaceutics and is interested and has been awarded funding in the areas of co-crystallisation of pharmaceutical materials at high pressure (EPSRC Early Career Fellowship) and polymorphism and polymerisation of monomeric materials (Leverhulme Trust 2012-2015).
Iain has contributed to the MPharm program as the 4th Year Co-ordinator (2012-2016) and has been an integral part of the redevelopment of the MPharm curriculum. He lectures and is class coordinator for the 2nd year class Pharmaceutics and for the Year 2 class Normal Function of the gastrointestinal tract. Students in the 4th year of study will be able to work with Iain on research associated with pharmaceutical products in the solid state. His teaching activities extend to postgraduate degrees in the MRes Drug Delivery Systems and MSc Pharmaceutical Analysis course.
Professional activities
- Under pressure to react - acetylenedicarboxylic acid polymerisation
- Speaker
- 28/8/2017
- BCA Chemical Crystallography Group Meeting
- Organiser
- 18/11/2015
- BCA Industrial group meeting
- Invited speaker
- 12/11/2015
- SciX 2015
- Invited speaker
- 27/9/2015
- IUCr 2014 International Union of Crystallography Congress
- Participant
- 3/8/2014
- Young Crystallographers Satellite Meeting, British Crystallographic Association 2014
- Keynote/plenary speaker
- 7/4/2014
more professional activities
Projects
- assess the potential for API particle shape control in API crystallisation processes (Student Placement Lauren Connor)
- Oswald, Iain (Principal Investigator)
- Period 13-Nov-2017 - 31-Mar-2018
- Evaluation of solid-state form for polymer drug delivery
- Oswald, Iain (Principal Investigator)
- Period 01-Jan-2017 - 31-Dec-2017
- Doctoral Training Partnership (DTP - University of Strathclyde) | Bebiano, Suse Vanessa
- Oswald, Iain (Principal Investigator) Ter Horst, Joop (Co-investigator) Bebiano, Suse Vanessa (Research Co-investigator)
- Period 01-Oct-2015 - 01-Apr-2019
- Allergan - Preliminary test
- Oswald, Iain (Principal Investigator)
- Period 02-May-2016 - 01-Jun-2016
- Co-crystallisation consultancy
- Oswald, Iain (Principal Investigator)
- Period 01-Dec-2015 - 01-Apr-2016
- Doctoral Training Centre In Continuous Manufacturing And Crystallisation | Turner, Alice
- Halbert, Gavin (Principal Investigator) Oswald, Iain (Principal Investigator) Florence, Alastair (Co-investigator) Johnston, Blair (Co-investigator) Turner, Alice (Research Co-investigator)
- Oral drug delivery is currently the preferred method of administration, making up 50% of the market, as it is relatively inexpensive and often has higher patient compliance than other methods. However, not all drugs are ideally suited to this method of administration, as many exhibit poor solubility or poor permeability, as observed in Class II and IV, and, III and IV of the Biopharmaceutical Classification System (BCS) respectively. Drugs with poor solubility are of particular concern as they often fail to fully dissolve in the gastrointestinal fluid and thus their absorption into the systemic circulation can be intermittant and insufficient leading to a greater risk of underdosing, poor bioavailability and diminished therapeutic effect. This can result in poor patient compliance as a result of breakthrough symptoms. However, for BCS Class II drugs it has been found that increased solubility exerted by a solid state modification or formulation can often result in bioavailability similar to that of the more soluble Class I drugs. Although a number of methods to increase solubility already exist there is a need for dosage forms which reduce the damage to the drug and are more flexible to the needs of the patient. Also in terms of the work of CMAC, there is a growing need for continuous methods of dosage form manufacture to reduce costs to the pharma and increase the overall quality of the final product. As such the current study aims to find an innovative formulation method to increase the solubility of pooly soluble drugs. This may be achieved by dramatically changing the way many oral dosage forms are manufactured currently. With a view to reducing the risk of polymorphic changes and degradation, the conventional steps of granulation, drying and compression will be replaced. Dosage forms will be produced by inkjet printing using an aerosol jet printer which has never been used in the pharma field before. It is hoped this will give production a degree of precision with regards to drug distribution, and thus release and overall performance, unrivaled by conventional techniques. It is hoped this will allow the resultant dosage forms to be tailored to the needs of the patient in terms of release time and dose. Due to the reduced number of processing steps and the fact the system can be used in an entirely continuous manner it is hoped this will result in less damage to the drug and a better quality of product. Previous studies have found inkjet printing to be very effective in solibilising class II drugs so it is hoped that the current study will follow this trend.
- Period 01-Oct-2014 - 01-Oct-2018
more projects
Address
Strathclyde Institute of Pharmacy and Biomedical Sciences
John Arbuthnott Building Robertson Wing
John Arbuthnott Building Robertson Wing
Location Map
View University of Strathclyde in a larger map
